Elotuzumab ( DrugBank: Elotuzumab )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 28 | 全身性アミロイドーシス | 1 |
| 300 | IgG4関連疾患 | 1 |
28. 全身性アミロイドーシス
臨床試験数 : 261 / 薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03252600 (ClinicalTrials.gov) | August 25, 2017 | 24/7/2017 | Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis | Recurrent Primary Amyloidosis | Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Elotuzumab;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Pharmacological Study | Barbara Ann Karmanos Cancer Institute | National Cancer Institute (NCI);Bristol-Myers Squibb;Multiple Myeloma Research Consortium | Active, not recruiting | 18 Years | N/A | All | 53 | Phase 2 | United States |
300. IgG4関連疾患
臨床試験数 : 36 / 薬物数 : 49 - (DrugBank : 22) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 98
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04918147 (ClinicalTrials.gov) | October 13, 2021 | 4/6/2021 | Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) | Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) | IgG4 Related Disease;IgG4-RD | Drug: elotuzumab;Drug: placebo for elotuzumab;Drug: methylprednisolone;Drug: diphenhydramine;Drug: acetaminophen;Drug: famotidine;Drug: prednisone | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence;Bristol-Myers Squibb;Rho Federal Systems Division, Inc. | Active, not recruiting | 18 Years | 70 Years | All | 75 | Phase 2 | United States |